New Study: Vaccine Manufacturers and FDA Regulators Used Statistical Gimmicks to Hide Risks of HPV Vaccines
A new study published in Clinical Rheumatology exposes how vaccine manufacturers used phony placebos in clinical trials to conceal a wide range of devastating risks associated with HPV vaccines. Instead of using genuine inert placebos and comparing health impacts over a number of years, as is required for most new drug approvals, Merck and GlaxoSmithKline spiked their placebos with a neurotoxic aluminum adjuvant and cut observation periods to a matter of months.
Researchers from Mexico’s National Institute of Cardiology pored over 28 studies published through January 2017—16 randomized trials and 12 post-marketing case series—pertaining to the three human papillomavirus (HPV) vaccines currently on the market globally. In their July 2017 peer-reviewed report, the authors, Manuel Martínez-Lavin and Luis Amezcua-Guerra, uncovered evidence of numerous adverse events, including life-threatening injuries, permanent disabilities, hospitalizations, and deaths, reported after vaccination with GlaxoSmithKline’s bivalent Cervarix vaccine and Merck’s quadrivalent or nine-valent HPV vaccines (Gardasil and Gardasil 9). Pharmaceutical company scientists routinely dismissed, minimized or concealed those injuries using statistical gimmicks and invalid comparisons designed to diminish their relative significance.
“Of the 16 HPV vaccine randomized trials, only two used an inert saline placebo. Ten of the sixteen compared the HPV vaccine against a neurotoxic aluminum adjuvant.”
Scientific researchers view double-blind placebo trials as the gold standard for testing new drugs. To minimize bias, investigators randomly assign patients to either a “treatment” group or a “control” (placebo) group and then compare health outcomes. The standard practice is to compare a new drug against a “pharmacologically inert” placebo. To minimize opportunities for bias, neither patients nor researchers know which individuals received the drug and which the placebo. However, in clinical trials of the various HPV vaccines, pharmaceutical researchers avoided this kind of rigor and instead employed sleight-of-hand flimflams to mask the seriousness of vaccine injuries.
Of the 16 HPV vaccine randomized trials, only two used an inert saline placebo. Ten of the sixteen compared the HPV vaccine against a neurotoxic aluminum adjuvant, and four trials used an already-approved aluminum-containing vaccine as the comparison. One does not have to be a scientist to understand that using aluminum-containing placebos is likely to muddy the comparison between the treatment and control groups.
Study: Cervical cancer vaccine may not be cause of health issues
A national survey conducted in response to mysterious health problems that girls and young women say were suffered after cervical cancer vaccinations has found that unvaccinated teenagers have reported similar symptoms in comparable numbers.
The results of the study were reported at a health ministry’s cervical cancer vaccine review committee meeting on Dec. 26.
The investigation was conducted by a health ministry research team headed by Tomotaka Sobue, a professor of public health at Osaka University.
The team asked about 18,000 clinics and hospitals in Japan whether they received female patients aged between 12 and 18, during the six-month period of July to December 2015, who complained of certain symptoms, including unexplained body pains and mobility problems, which persisted for more than three months.
The study also asked about the degree to which the patients were affected by the conditions and whether they have difficulty in commuting to school or work.
Analysis of the health-care providers’ responses showed that the ratio of girls who had the cervical cancer vaccination and reported those conditions was 27.8 per 100,000 people. By comparison, the ratio was 20.4 per 100,000 people for the unvaccinated girls experiencing the conditions.
The survey was undertaken to provide evidence to help determine whether active promotion of the cervical cancer vaccinations, which has been halted since 2013, should be resumed.
Why flu vaccines so often fail
By Jon CohenSep. 20, 2017 , 2:30 PM
The influenza virus has yet to hit the Northern Hemisphere, but flu vaccine season is already in full swing, with banners outside pharmacies urging: “Get Your Flu Shot Now.” What’s not advertised, however, is just how lackluster the vaccine is. The most commonly used flu shots protect no more than 60% of people who receive them; some years, effectiveness plunges to as low as 10%. Given that a bad flu season can kill 50,000 people in the United States alone, “10% to 60% protection is better than nothing,” says Michael Osterholm, an epidemiologist at the University of Minnesota in Minneapolis. “But it’s a terribly inadequate vaccine for a serious public health threat.” Now, researchers are striving to understand why it fails so often—and how to make a markedly better one.
They’re questioning what was once received wisdom: that the vaccine fails when manufacturers, working months ahead of flu season, incorrectly guess which strains will end up spreading. And they’re learning instead that the vaccine may falter even when the right strains were used to make it, perhaps because of how it is produced or quirks of individual immune systems. “It’s much more complicated than we thought,” Osterholm says. “I know less about influenza today than I did 10 years ago.”
Measles Virus Neutralizing Antibodies in Intravenous Immunoglobulins:is an Increase by Re-Vaccination of Plasma Donors possible?
We report a screen of plasma donors which confirmed that widespread use of childhood measles vaccination since 1963 resulted in a decrease of average measles virus antibody titers in plasma donors, which is reflected in intravenous immunoglobulins (IVIG). The measles virus antibody titer is, however, a potency requirement for IVIG, as defined in FDA regulation. To mitigate the decline in measles virus antibody titers in IVIG and to ensure consistent product release, re-vaccination of plasma donors was investigated as a means to boost titers. However, re-vaccination induced titer increases were only about two-fold, and short lived.
Baby Foreskin Is Being Used To Make Vaccines
Warning: Some people may find the information in this article disturbing and the images graphic.
Every year, some infants are circumcised. During this surgical procedure, part of the child’s protective penile tissue is removed. This tissue removed from his penis may be sold to companies and institutions seeking the rich human fibroblast cells and other cells it contains. Most people are unaware that for decades, vaccine companies have been using these foreskin cells to research, grow and develop vaccines.
Certain microorganisms used by vaccine companies need living human cells to replicate. The cells within foreskin are being used for this purpose. Foreskin cells can be used to turn a wild-type microorganism found in nature into a genetically modified microorganism for use in vaccines.
Baby foreskins are used to research rubella, varicella and human papillomavirus (HPV) vaccines. They are used to make cytomegalovirus vaccines, which is something pharmaceutical companies have been working on the last few decades. This vaccine is being created using foreskin cells and clinical trials have already begun. The child’s DNA whose foreskin was used to make the vaccine cannot be fully removed from the vaccines prior to administration. Researchers are also using foreskin to create a human telomerase reverse transcriptase (hTERT) immortalized cell line for use in vaccines.
Cells isolated from infant foreskin are preferred because the infant cells have a longer lifespan than those isolated from adult foreskin. The ongoing issue with companies using infant foreskin to develop vaccines and other products is vast; only a small fraction can be discussed here. It is important to research how vaccines are made prior to receiving them, if you want to avoid unwanted contaminants in your body.
PDF: 17 Examples of Admitted Vaccine Failure
Doctor Who Warned Families About Vaccine Dangers, Found Dead Body of missing Dr. Peter Cianfrani found by searchers
By: Jay Greenberg |@NeonNettle on 28th September 2017
A doctor who warned families about the dangers of mandatory vaccines has been found dead a day after he was reported missing. The body of Dr. Peter Cianfrani, 70, was discovered by search teams on Wednesday morning just off of the Perkiomen Trail in Montgomery County, Pennsylvania. The longtime family doctor, who disappeared Tuesday was discovered in an isolated woodland area near a trail by searchers. The Perkiomen Trail is a 19-mile-long multi-use rail trail along the Perkiomen Creek, with the trail mostly being gravel. Although the trail is popular with hikers, it’s unclear why Dr. Cianfrani was up there or why his body was found in a wooded area away from the trail. The cause and manner of death are pending although police claim that his death is most-likely a suicide and won’t be investigated as “suspicious”. Dr. Cianfrani had worked in Montgomery County as a medical practitioner for years and was a well-trusted family doctor.
BOOK – Pasteur: Plagiarist, Imposter by R. B. Pearson
Metro Detroit mom could be thrown behind bars for not getting son vaccinated
11:14 PM, Sep 27, 2017
(WXYZ) – If you have kids, their health, their safety is your top priority.
However, what if doing what you think is best, could land you behind bars?
A Metro Detroit mother is facing jail time because of her beliefs when it comes to vaccinations and her kid.
“I would rather sit behind bars standing up for what I believe in, than giving in to something I strongly don’t believe in,” says Rebecca Bredow.
Bredow, a mother of two, has one week to get her son vaccinated and if she does not comply with the order of an Oakland County judge, she will be thrown in jail.
Rebecca believes in parents having the choice to make the right decision for their children based on the parent’s knowledge of vaccines and the child
Mutant Strains Of Polio Vaccine Now Cause More Paralysis Than Wild Polio
June 28, 2017
For the first time, the number of children paralyzed by mutant strains of the polio vaccine are greater than the number of children paralyzed by polio itself.
So far in 2017, there have been only six cases of “wild” polio reported anywhere in the world. By “wild,” public health officials mean the disease caused by polio virus found naturally in the environment.
By contrast, there have been 21 cases of vaccine-derived polio this year. These cases look remarkably similar to regular polio. But laboratory tests show they’re caused by remnants of the oral polio vaccine that have gotten loose in the environment, mutated and regained their ability to paralyze unvaccinated children
Study – IgE sensitization to gelatin: the probable role of gelatin-containing diphtheria–tetanus–acellular pertussis (DTaP) vaccines
We recently found that most events of anaphylaxis to live attenuated viral vaccines containing gelatin as a stabilizer might be caused by the gelatin. However, the mechanism that the children were sensitized to gelatin was unclear. In Japan, both diphtheria–tetanus–acellular pertussis (DTaP) vaccines with and without gelatin are available. We explored the possibility that gelatin-containing DTaP vaccines before live viral vaccines sensitize children to gelatin. We received the serum samples of 87 children who had systemic immediate-type reactions including anaphylaxis to the vaccines from both physicians and vaccine manufacturers throughout Japan. We then surveyed the DTaP vaccination histories of the children who demonstrated anti-gelatin IgE. Of the above 87 children, 79 (91%) had anti-gelatin IgE. We successfully collected DTaP vaccination histories including the manufacturers’ names and numbers of doses on 55 children. Only one child had not received any DTaP vaccine, the other 54 had received gelatin-containing DTaP vaccines and none received gelatin-free DTaP vaccines. We concluded that there was a strong causal relationship between gelatin-containing DTaP vaccination, anti-gelatin IgE production, and risk of anaphylaxis following subsequent immunization with live viral vaccines which contain a larger amount of gelatin.